# Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy

> **NCT00272870** · PHASE1 · TERMINATED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 1 (actual)

## Conditions studied

- Glioblastoma Multiforme (WHO Grade IV)
- Anaplastic Astrocytoma (WHO Grade III)

## Interventions

- **DRUG:** 06Benzylguanine
- **GENETIC:** MGMT P140K
- **DEVICE:** Meltenyi CliniMacs

## Key facts

- **NCT ID:** NCT00272870
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-12
- **Primary completion:** 2008-12
- **Final completion:** 2012-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow accrual; drug availability
- **Last updated:** 2012-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272870, "Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00272870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*